Search

Displaying results 5081 - 5090 of 7180 in total
  1. Drug

    Typhoid Vaccine Live

    go.drugbank.com/drugs/DB11050
    ApprovedInvestigational

    The vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by *Salmonella typhi* by inducing a local immune response in the intestinal tract.

  2. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment of Crohn's Disease. The drug is co...

  3. Drug

    Fludiazepam

    go.drugbank.com/drugs/DB01567
    IllicitInvestigational

    It is a scheduled drug in the U.S., but is approved for use in Japan.

    Synonyms: 7-chloro-5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one
  4. Drug

    ONO-2952

    go.drugbank.com/drugs/DB14802
    Investigational

    ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable

  5. Drug

    Biricodar

    go.drugbank.com/drugs/DB04851
    Investigational

    The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

  6. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tum...

  7. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency. [L2917]

  8. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  9. Drug

    Guanosine tetraphosphate

    go.drugbank.com/drugs/DB04022
    Experimental

    Two phosphate groups are esterified to the sugar moiety in the 5' position and the other two in the 2' or 3' position. … This nucleotide serves as a messenger to turn off the synthesis of ribosomal RNA when amino acids are not available for protein synthesis.

  10. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.